6 completed, 1 active not recruiting, 1 recruiting, 1 terminated. 10 Phase 2, 3 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Completed 6, Active not recruiting 1, Recruiting 1, Terminated 1, Unknown 1 |
| Phase 3 | 3 | Completed 2, Unknown 1 |
| Phase 1 | 1 | Active not recruiting 1 |
Follow Thalassemia Major: new trials by email Literature Review of Thalassemia Major trials Research Report on Thalassemia Major
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Unraveling the Impact of Thalidomide at Diverse Doses in Transfusion Dependent Beta Thalassemia Thalidomide - Fetal Hemoglobin, Thalassemia Major | Phase 2 | Recruiting | National Institute of Blood and Marrow Transplant (NIBMT), Pakistan | 54 | 2024-04-22 | 2025-05-30 |
| EDIT-301 for Autologous Hematopoietic Stem Cell Transplant (HSCT) in Participants With Transfusion-Dependent Beta Thalassemia (TDT) EDIT-301 - Transfusion Dependent Beta Thalassemia, Hemoglobinopathies | Phase 1 / Phase 2 | Active not recruiting | Editas Medicine, Inc. | 9 | 2022-04-29 | 2025-04-02 |
| Hydroxy Urea, Omega 3, Nigella Sativa,Honey on Oxidative Stress and Iron Chelation in Pediatric Major Thalassemia Omega 3, Nigella Sativa Oil, Hydroxyurea - Iron Overload, Oxidative Stress | Phase 2 / Phase 3 | Completed | Beni-Suef University | 350 | 2019-11-01 | 2021-01-27 |
| Pilot Study to Assess the Safety, PK and Iron Chelating Activity of DST-0509 (Deferasirox) in Thalassemia Patients Refractory to Chelation DST-0509, Jadenu, Exjade - Thalassemia Major | Phase 2 | Completed | DisperSol Technologies, LLC | 25 | 2019-08-20 | 2022-02-01 |
| Denosumab vs Placebo in Patients With Thalassemia Major and Osteoporosis Denosumab, Placebo - Thalassemia Major, Osteoporosis | Phase 2 | Completed | Ersi Voskaridou | 63 | 2014-09-01 | 2019-08-26 |
| Study of Efficacy and Safety of INC424 in Regularly Transfused Patients With Thalassemia. ruxolitinib - Thalassemia Major | Phase 2 | Completed | Novartis Pharmaceuticals | 30 | 2014-05-28 | 2017-07-17 |
| Role of Vitamin C to Augment Iron Chelation With DFP or DFX Vitamin C, Defriprone, deferisarox, deferiprone , deferesarox - Vitamin c, Thalassemia Major | Phase 2 / Phase 3 | Unknown | Ain Shams University | 50 | 2014-04-01 | 2014-03-11 |
| Amlodipine Use in the Prevention and Treatment of Iron Overload in Patients With Thalassemia Major Amlodipine - Thalassemia Major | Phase 2 / Phase 3 | Completed | University of Campinas, Brazil | 10 | 2008-09-01 | 2015-01-05 |
| Efficacy and Safety of Neridronate (Nerixia®)to Treat Osteoporosis in Patients With TM and TI Neridronate - Osteoporosis, Thalassemia Major | Phase 2 | Completed | Ente Ospedaliero Ospedali Galliera | 120 | 2004-01-01 | 2020-02-05 |
| Stem Cell Transplantation After Reduced-Dose Chemotherapy for Patients With Sickle Cell Disease or Thalassemia Busulfan, Fludarabine, FK506 - Hemoglobinopathies, Anemia, Sickle Cell | Phase 2 | Terminated | National Institute of Allergy and Infectious Diseases (NIAID) | 2 | 2001-09-01 | 2013-05-01 |
beta-Thalassemia (10) · Thalassemia (5) · Hemoglobinopathies (2) · Osteoporosis (2) · Anemia, Sickle Cell (1) · Bone Diseases, Metabolic (1) · Genetic Diseases, Inborn (1) · Hemoglobin SC Disease (1) · Iron Overload (1) · Splenomegaly (1)
Anemia (10) · Anemia, Hemolytic (10) · Anemia, Hemolytic, Congenital (10) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (10) · Hematologic Diseases (10) · Hemic and Lymphatic Diseases (10) · Genetic Diseases, Inborn (9) · Hemoglobinopathies (8) · Thalassemia (5) · Metabolic Diseases (3) · Nutritional and Metabolic Diseases (3) · Bone Diseases (2) · Musculoskeletal Diseases (2) · Bone Diseases, Metabolic (1) · Hypertrophy (1)
6-amino-1-hydroxyhexane-1,1-diphosphonate (1) · Amlodipine (1) · Ascorbic Acid (1) · Busulfan (1) · Deferasirox (1) · Deferiprone (1) · Deferoxamine (1) · Denosumab (1) · Docosahexaenoic Acids (1) · Honey (1) · Hydroxyurea (1) · Isoflurophate (1) · Nigella sativa oil (1) · Prednisone (1) · Tacrolimus (1)
Ain Shams University (1) · Beni-Suef University (1) · DisperSol Technologies, LLC (1) · Editas Medicine, Inc. (1) · Ente Ospedaliero Ospedali Galliera (1) · Ersi Voskaridou (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · National Institute of Blood and Marrow Transplant (NIBMT), Pakistan (1) · Novartis Pharmaceuticals (1) · University of Campinas, Brazil (1)
United States (3) · Egypt (2) · Greece (2) · Italy (2) · Thailand (2) · Brazil (1) · Canada (1) · Lebanon (1) · Pakistan (1) · Saudi Arabia (1) · Turkey (Türkiye) (1)
Ahmed F Mahmoud Hussein, MS.c (1) · Catherine J. Wu, MD (1) · Ernesto Palummeri, MD (1) · Ersi Voskaridou, Doctor (1) · Gian Luca Forni, MD (1) · Juliano L Fernandes, MD (1)
PMID 14550808, PMID 22571408, PMID 30381400, PMID 32395210, PMID 37975597, PMID 41931048
2014 (1)